Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ascendis Pharma Ads
(NQ:
ASND
)
146.91
USD
+3.46 (+2.41%)
Official Closing Price
Updated: 5:08 PM EST, Mar 5, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
239,000
Open
144.66
Bid (Size)
146.44 (1)
Ask (Size)
146.91 (6)
Prev. Close
143.45
Today's Range
136.58 - 146.91
52wk Range
92.00 - 183.98
Shares Outstanding
41,779,122
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
March 04, 2021
From
GlobeNewswire News Releases
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
February 26, 2021
From
GlobeNewswire News Releases
Performance
YTD
-11.23%
-11.23%
1 Month
-2.63%
-2.63%
3 Month
-14.54%
-14.54%
6 Month
+2.64%
+2.64%
1 Year
+13.07%
+13.07%
More News
Read More
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
February 18, 2021
From
GlobeNewswire News Releases
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
January 10, 2021
From
GlobeNewswire News Releases
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
January 08, 2021
From
PR Newswire
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
January 08, 2021
From
GlobeNewswire News Releases
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
January 07, 2021
From
PR Newswire
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
January 26, 2021
From
Business Wire News Releases
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
From
GlobeNewswire News Releases
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
December 30, 2020
From
GlobeNewswire News Releases
Ascendis Pharma A/S Announces Planned Board Transition
December 14, 2020
From
GlobeNewswire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.